Immunomodulatory Effects of Hemagglutinin- (HA-) Modified A20 B-Cell Lymphoma Expanded as a Brain Tumor on Adoptively Transferred HA-Specific CD4+ T Cells
Figure 7
HA-specific CD4+ T cells from spleen of symptomatic mice versus asymptomatic are refractory to restimulation with HA peptide in vitro after HA vaccination in vivo. (a) Percent of HA-specific CD4+ Thy-1.1+ T cells measured by FASC, (b) proliferative response measured by [3H]TdR incorporation, and (c) concentration of IFN-γ in the supernatants measured by ELISA on day 18 after the adoptive transfer. HA-specific CD4+Thy1.1+ T cells were injected i.v. into A20HA brain tumor-bearing mice on day 5 after i.c. tumor inoculation. Virus HA-Vac was delivered i.p. on day 15 after the adoptive transfer. Individual spleens from asymptomatic (As) and symptomatic (Sy) mice were isolated 3 days later, and cell cultures were analyzed after 72 h incubation with or without HA peptide in triplicate wells. A20HA + T cells + HA-Vac, mice that received A20HA tumor cells, HA-specific CD4+Thy1.1+ T cells, and virus HA-Vac; A20HA + T cells, mice that received A20HA tumor cells and HA-specific CD4+Thy1.1+ T cells; T cells + HA-Vac, mice that received HA-specific CD4+Thy1.1+ T cells and virus HA-Vac; T cells, mice that received only HA-specific CD4+Thy1.1+ T cells. Numbers under axis in (c) show IFN-γ concentrations. Data are represented as the mean ± SD, . .
